#India #Ahmedabad #Oncology Diagnostics #Elephas Biosciences #Neuberg Diagnostics

Elephas Biosciences Forms Strategic Alliance with Neuberg Diagnostics in India

In a significant move aiming to revolutionize oncology diagnostics in India, Elephas Biosciences Corporation has announced a groundbreaking exclusive partnership with Neuberg Diagnostics, a leading entity in pathology and molecular diagnostics. This collaboration combines the innovative capabilities of Elephas’ live tissue platform with Neuberg’s extensive diagnostic expertise, allowing for improved prediction of immunotherapy responses for cancer patients.

The Vision Behind the Partnership

The newly formed alliance marks a crucial step in Elephas' global commercialization strategy. The company has developed a unique ex vivo platform called elive™, designed specifically for assessing how live tumor tissues respond to various oncology therapies. By preserving the native tumor microenvironment through a live core needle biopsy, Elephas aims to provide functional insights that can inform better treatment decisions for oncologists. With the advent of this partnership, Neuberg is set to integrate the elive™ platform into its laboratory infrastructure, with plans to launch clinical tests by the end of 2026.

Maneesh Arora, the founder and CEO of Elephas, expressed excitement about the collaboration, emphasizing Neuberg's reputation as a leader in oncology diagnostics across India. The partnership is anticipated to not only enhance testing capabilities but also to facilitate the use of functional immunotherapy response assessments in clinical practices, bringing a new level of precision to cancer care.

Advantages of Joining Forces

This collaboration capitalizes on both entities' strengths, combining Neuberg's established knowledge in oncology diagnostics with Elephas’ cutting-edge technology. According to Dr. Sandip Shah, Joint Managing Director at Neuberg Diagnostics, understanding which patients will benefit from immunotherapy remains one of the most complex challenges in cancer treatment. The integration of functional response data alongside molecular profiling is expected to yield higher confidence and speed in directing patients towards the most effective therapies.

Neuberg will also act as a research partner in this initiative, leveraging its flagship laboratory in Ahmedabad to process tumor biopsy samples utilizing the elive platform. This engagement will generate critical local evidence supporting the platform's efficacy as they work towards broader adoption within the Indian healthcare system, further solidifying the innovation landscape in oncology care.

The Landscape of Oncology in India

With cancer projected to become a leading cause of morbidity and mortality worldwide, access to personalized medicine is increasingly paramount. The partnership between Elephas and Neuberg promises to bridge gaps in healthcare access through cutting-edge technology that can deliver precise diagnostics and optimize treatment plans.

Elephas is on a mission to combat the growing challenge posed by cancer, which is expected to see patient numbers triple by 2060. While therapeutic options such as immunotherapies and targeted therapies have surged, only a small percentage of patients show favorable responses due to a lack of accurate predictive biomarkers. The elive™ platform seeks to address this issue by enabling clinicians to evaluate live tumor responses to therapies, offering insights that were previously unattainable.

Neuberg Diagnostics, headquartered in Chennai, is recognized as one of India’s premier diagnostic service providers, boasting a presence across various regions including the UAE, South Africa, and the USA. The collaboration is expected to further the objectives of both organizations in making state-of-the-art diagnostic technologies accessible, featuring a talented team of clinical pathologists, oncopathologists, and certified lab professionals.

As the partnership kicks off, the healthcare community remains optimistic about the implications for patient outcomes in oncology, paving the way for improved treatment efficacy and better management of cancer care in India. As Elephas and Neuberg make strides in their mission, they may very well redefine the landscape of personalized oncology diagnostics and therapy in the region and beyond.

For more information on their initiatives, visit Elephas Biosciences and stay connected through their LinkedIn page.